Literature DB >> 15724433

Evaluation of serum lipids and high-density lipoprotein subfractions (HDL2, HDL3) in postmenopausal patients with breast cancer.

V Michalaki1, G Koutroulis, K Syrigos, C Piperi, A Kalofoutis.   

Abstract

Breast cancer patients are known to be at increased risk for developing other chronic diseases including cardiovascular disease. Studies by different investigators have shown a correlation between increased dietary fat or hypercholesterolemia and the occurrence of breast cancer. Since previous studies on lipoprotein subfractions in this type of cancer have been inconsistent, we evaluated the lipids and lipoprotein subfraction levels in postmenopausal patients with breast cancer in an attempt to identify the risk for the development of cardiovascular disease. The study included 132 patients, 56 of which were suffering from breast cancer, 32 from pancreatic and 44 age-matched controls. Total cholesterol (TC), triglycerides and lipoprotein fractions as well as TC/High density lipoprotein (HDL) and HDL2/HDL3 ratios were estimated by standard laboratory techniques. An increase in triglycerides and a decrease in HDL-cholesterol, especially in the HDL2 subfraction, were observed in patients with breast cancer as compared to the controls (P < 0.05). The maximum changes in TC, and HDL concentrations were observed in patients with advanced disease. Analysis of indexes of atherosclerosis (TC/HDL, and HDL2/HDL3 ratios) demonstrated that breast cancer patients had significantly higher TC/HDL ratio (6.44+/-1.24) compared with controls (3.43+/-0.57, p = 0.001), and patients with pancreatic cancer (3.79+/-0.15, p = 0.027). The results have demonstrated an unfavourable lipid profile in untreated breast cancer patients with high atherosclerosis indexes. This observation is of great importance, considering the potential use of endocrine therapy that could result in further deterioration of lipid indexes. We propose the evaluation and monitoring of lipid profile prior and after the induction of hormonal therapy in breast cancer patients, as a routine in clinical setting.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15724433     DOI: 10.1007/s11010-005-2993-4

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  31 in total

1.  On a possible inverse relationship between serum cholesterol and cancer mortality.

Authors:  M Feinleib
Journal:  Am J Epidemiol       Date:  1981-07       Impact factor: 4.897

Review 2.  Lipoprotein subspecies and risk of coronary disease.

Authors:  T A Musliner; R M Krauss
Journal:  Clin Chem       Date:  1988       Impact factor: 8.327

3.  Effect of letrozole on the lipid profile in postmenopausal women with breast cancer.

Authors:  M S Elisaf; E T Bairaktari; C Nicolaides; B Kakaidi; C S Tzallas; A Katsaraki; N A Pavlidis
Journal:  Eur J Cancer       Date:  2001-08       Impact factor: 9.162

4.  The clinical and biologic significance of abnormal lipid profiles in patients with myelodysplastic syndromes.

Authors:  K Allampallam; D Dutt; C Nair; V Shetty; S Mundle; L Lisak; C Andrews; B Ahmed; L Mazzone; F Zorat; R Borok; M Muzammil; A Gundroo; I Ansaarie; A Raza
Journal:  J Hematother Stem Cell Res       Date:  2000-04

Review 5.  Low cholesterol and cancer.

Authors:  H Kritz; C Zielinski; H Sinzinger
Journal:  J Clin Oncol       Date:  1996-11       Impact factor: 44.544

6.  Hypocholesterolaemia in malignancy due to elevated low-density-lipoprotein-receptor activity in tumour cells: evidence from studies in patients with leukaemia.

Authors:  S Vitols; G Gahrton; M Björkholm; C Peterson
Journal:  Lancet       Date:  1985-11-23       Impact factor: 79.321

7.  Serum lipids and apolipoproteins in women with breast masses.

Authors:  D M Lane; K K Boatman; W J McConathy
Journal:  Breast Cancer Res Treat       Date:  1995-05       Impact factor: 4.872

8.  High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study.

Authors:  T Gordon; W P Castelli; M C Hjortland; W B Kannel; T R Dawber
Journal:  Am J Med       Date:  1977-05       Impact factor: 4.965

9.  Association between high-density lipoprotein cholesterol and breast cancer varies by menopausal status.

Authors:  P G Moorman; B S Hulka; R A Hiatt; N Krieger; B Newman; J H Vogelman; N Orentreich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  1998-06       Impact factor: 4.254

10.  Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study.

Authors:  G Assmann; H Schulte
Journal:  Am J Cardiol       Date:  1992-09-15       Impact factor: 2.778

View more
  26 in total

Review 1.  The metabolic syndrome: A high-risk state for cancer?

Authors:  Stephanie Cowey; Robert W Hardy
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

2.  Elevated apolipoprotein A-I levels are associated with favorable prognosis in metastatic nasopharyngeal carcinoma.

Authors:  Rou Jiang; Zhong-Han Yang; Dong-Hua Luo; Ling Guo; Rui Sun; Qiu-Yan Chen; Pei-Yu Huang; Fang Qiu; Xiong Zou; Ka-Jia Cao; Hai-Qiang Mai; Xiang Guo; Chao-Nan Qian; Ming-Huang Hong; Ming-Yuan Chen
Journal:  Med Oncol       Date:  2014-07-15       Impact factor: 3.064

3.  Correlation of apolipoprotein A-I kinetics with survival and response to first-line platinum-based chemotherapy in advanced non-small cell lung cancer.

Authors:  Ting Cheng; Xin Dai; Dan-Li Zhou; Yang Lv; Li-Yun Miao
Journal:  Med Oncol       Date:  2014-12-03       Impact factor: 3.064

4.  Correlation Between Obesity and High Density Lipoprotein Cholesterol (HDL-C) in Breast Cancer Patients of Southern Rajasthan.

Authors:  Padmanabh Inamdar; Garima Mehta
Journal:  Indian J Surg Oncol       Date:  2011-05-06

5.  27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth.

Authors:  Qian Wu; Tomonori Ishikawa; Rosa Sirianni; Hao Tang; Jeffrey G McDonald; Ivan S Yuhanna; Bonne Thompson; Luc Girard; Chieko Mineo; Rolf A Brekken; Michihisa Umetani; David M Euhus; Yang Xie; Philip W Shaul
Journal:  Cell Rep       Date:  2013-11-07       Impact factor: 9.423

Review 6.  Lipid mechanisms in hallmarks of cancer.

Authors:  J Molendijk; H Robinson; Z Djuric; M M Hill
Journal:  Mol Omics       Date:  2020-02-17

7.  Metabolic syndrome and outcomes following early-stage breast cancer.

Authors:  Gregory S Calip; Kathleen E Malone; Julie R Gralow; Andy Stergachis; Rebecca A Hubbard; Denise M Boudreau
Journal:  Breast Cancer Res Treat       Date:  2014-10-10       Impact factor: 4.872

8.  Association of metabolic syndromes and risk factors with ampullary tumors development: a case-control study in China.

Authors:  Xiao-Dong He; Qiao Wu; Wei Liu; Tao Hong; Jing-Jing Li; Ruo-Yu Miao; Hai-Tao Zhao
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

9.  Prognostic nomogram integrated baseline serum lipids for patients with non-esophageal squamous cell carcinoma.

Authors:  Shulin Chen; Xiaohui Li; Xiaoyan Wen; Songguo Peng; Ning Xue; Shan Xing; Yijun Liu
Journal:  Ann Transl Med       Date:  2019-10

10.  Metabolic profile of breast cancer in a population of women in southern Spain.

Authors:  Juan-Bosco Lopez-Saez; Jose Antonio Martinez-Rubio; Maria Montes Alvarez; Carmen Gonzalez Carrera; Margarita Dominguez Villar; Antonio Garcia de Lomas Mier; Charo Doménech; Avelino Senra-Varela
Journal:  Open Clin Cancer J       Date:  2008-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.